UCB SA (OTCMKTS:UCBJF) Short Interest Up 20.8% in March

Market Beat
2025.04.03 05:11

UCB SA (OTCMKTS:UCBJF) experienced a 20.8% increase in short interest in March, totaling 481,000 shares as of March 15th, up from 398,200 shares on February 28th. This represents 0.3% of the company's stock sold short, with a short-interest ratio of 155.2 days based on an average trading volume of 3,100 shares. The stock opened at $172.33, with a 50-day moving average of $190.96 and a 200-day moving average of $186.42. UCB specializes in biopharmaceuticals for neurology and immunology diseases.

UCB SA (OTCMKTS:UCBJF - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 481,000 shares, a growth of 20.8% from the February 28th total of 398,200 shares. Approximately 0.3% of the company's shares are short sold. Based on an average daily trading volume, of 3,100 shares, the short-interest ratio is presently 155.2 days.

UCB Stock Performance

UCBJF opened at $172.33 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The stock's 50 day moving average price is $190.96 and its 200-day moving average price is $186.42. UCB has a one year low of $123.00 and a one year high of $209.66.

About UCB

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Stories

  • Five stocks we like better than UCB
  • Learn Technical Analysis Skills to Master the Stock Market
  • D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
  • Insider Selling Explained: Can it Inform Your Investing Choices?
  • Amazon Falls Back to a Key Support Line: Here's How to Play It
  • Best Stocks Under $10.00
  • Buffett Trims Equities, But Still Keeps Buying This Stock

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in UCB Right Now?

Before you consider UCB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.

While UCB currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.